Trials / Completed
CompletedNCT04268628
A Study of Pharmacodynamic and Genetic Parameters of Abira-DES Study Participants (NCT02217566) - Participants With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Following Unresponsive Treatment With Diethylstilbestrol
Exploratory Evaluation of Genetic Polymorphism and Pharmacodynamic Parameters in Samples of Abira-DES Study Subjects (NCT02217566) - Subjects With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Following Unresponsive Treatment With Diethylstilbestrol.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 42 (actual)
- Sponsor
- Janssen-Cilag Farmaceutica Ltda. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to evaluate the influence of HSD3B1 (1245C) germline variant and potential pharmacodynamic markers on abiraterone activity in participants with metastatic castration-resistant prostate cancer after unresponsive use of diethylstilbestrol.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Serum and plasma samples analysis | This is a non-interventional study and no drug will be given as part of this study. Serum and plasma samples will be collected from the participants with metastatic castration-resistant prostate cancer to evaluate genetic polymorphism and pharmacodynamic parameters. |
Timeline
- Start date
- 2020-03-19
- Primary completion
- 2020-11-16
- Completion
- 2020-11-16
- First posted
- 2020-02-13
- Last updated
- 2022-01-03
Locations
1 site across 1 country: Brazil
Source: ClinicalTrials.gov record NCT04268628. Inclusion in this directory is not an endorsement.